Ovid Therapeutics Inc. (OVID) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Ovid Therapeutics reported revenue of $7.3M, up 1181.3% from $566,000 the year before. Net income was -$17.4M (a -240.1% net margin), or -$0.23 per diluted share. Operating margin was -585.2%. Operating activities generated -$38.3M of cash, leaving -$38.3M of free cash flow. At fiscal year end, Ovid Therapeutics held $150.9M in total assets against $20.3M in total liabilities, including $13.2M of cash and equivalents.
Open the full interactive Ovid Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Ovid Therapeutics Key Stats
| Share Price | $2.19 |
|---|---|
| Market Cap | $432.4M |
| 52-Week Range | $1.20 – $2.96 |
| Shares Outstanding | 197.5 million (basic, 2026 Q2) |
Ovid Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $12.6M | $208.4M | $1.5M | $391,695 | $566,000 | $7.3M |
| Operating Income | -$81.4M | $124.2M | -$55.5M | -$59.3M | -$61.9M | -$42.4M |
| Pre-Tax Income | -$81.0M | $124.2M | -$54.2M | -$52.3M | -$26.4M | -$17.4M |
| Income Tax | $0 | $1.3M | $0 | $0 | $0 | $0 |
| Net Income | -$81.0M | $122.8M | -$54.2M | -$52.3M | -$26.4M | -$17.4M |
| Diluted EPS | — | $1.76 | -$0.77 | -$0.74 | -$0.37 | -$0.23 |
Ovid Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $132,000 | $718,000 | $0 | $733,000 |
| Net Income | -$12.2M | $9.7M | -$17.0M | -$15.0M |
| Diluted EPS | -$0.17 | $0.13 | -$0.12 | -$0.08 |
Ovid Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $72.0M | $187.8M | $44.9M | $27.0M | $26.3M | $13.2M |
| Current Assets | $74.8M | $190.5M | $131.4M | $109.6M | $55.9M | $74.4M |
| Total Assets | $75.9M | $194.5M | $155.3M | $144.0M | $92.2M | $150.9M |
| Current Liabilities | $22.1M | $14.8M | $7.0M | $11.5M | $10.5M | $8.3M |
| Total Liabilities | $32.3M | $14.8M | $23.0M | $56.2M | $23.9M | $20.3M |
| Shareholders' Equity | $43.6M | $179.7M | $132.3M | $87.8M | $68.2M | $130.7M |
Ovid Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$51.6M | $118.6M | -$55.2M | -$45.8M | -$56.0M | -$38.3M |
| Cash From Investing | $34.6M | -$1.8M | -$87.9M | -$2.6M | $54.6M | -$49.9M |
| Cash From Financing | $47.1M | $904,082 | $180,658 | $30.5M | $622,000 | $75.2M |
| Free Cash Flow | -$51.7M | $118.4M | -$56.4M | -$45.8M | -$56.1M | -$38.3M |
Figures from Ovid Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Ovid Therapeutics financials page for every line item.
Ovid Therapeutics Company Profile
| Ticker | OVID |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | New York, New York |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001636651 |
Frequently Asked Questions
What was Ovid Therapeutics' revenue in fiscal 2025?
Ovid Therapeutics (OVID) reported revenue of $7.3M for fiscal 2025.
What is Ovid Therapeutics' annual revenue history?
Ovid Therapeutics' annual revenue by fiscal year: 2020: $12.6M; 2021: $208.4M; 2022: $1.5M; 2023: $391,695; 2024: $566,000; 2025: $7.3M.
What was Ovid Therapeutics' net income in fiscal 2025?
Ovid Therapeutics reported net income of -$17.4M for fiscal 2025.
What was Ovid Therapeutics' earnings per share (EPS) in fiscal 2025?
Ovid Therapeutics' diluted EPS was -$0.23 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Ovid Therapeutics generate in fiscal 2025?
Ovid Therapeutics generated -$38.3M of free cash flow in fiscal 2025.
What was Ovid Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Ovid Therapeutics reported revenue of $733,000.
How many shares of Ovid Therapeutics are outstanding?
Ovid Therapeutics reported a weighted average of 197.5 million basic shares outstanding in 2026 Q2.
What is Ovid Therapeutics' market cap?
Based on its latest closing price, Ovid Therapeutics (OVID) has a market capitalization of about $432.4M.
When does Ovid Therapeutics' fiscal year end?
Ovid Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Ovid Therapeutics headquartered?
Ovid Therapeutics lists its business address in New York, New York in its SEC filings.